arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PTC THERAPEUTICS, INC.

PTCT
$62.32 ▼ -3.60 (-5.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
91
Health
Excellent
Bullish
auto_awesome

Analytical Summary

PTC THERAPEUTICS, INC. shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.0B
Dividend Yield —
Revenue Growth 114.5% ↗
Op. Margin 50.1% ↗
ROIC -413.8% ↘
FCF / Share $8.83 ↗
Trailing P/E 7.3x
Price / Book —
FCF Yield 14.2%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.73B
↑ +114.5% —
Net Income Profit after all expenses
$682.64M
↑ +287.9% —
Operating Margin Operating profit as % of sales
50.1%
↑ +233.6% 97th
FCF / Share Free cash flow per share
$8.83
↑ +694.3% —
Long-Term Debt Long-term obligations
$285.41M
— +0.4% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
97
Financial Health
96
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 59 quarters